90-Second Read: Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development... May 28, 2026 07:25 ET | Source: Dyadic International, Inc. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic's control.

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. Dyadic has also previously demonstrated GMP-compliant manufacturing and Phase 1 clinical evaluation of biologics produced using its C1 platform as part of earlier infectious disease initiatives. Together, these programs continue to generate data that support the potential advantages of the C1 platform, including compressed development timelines, scalable microbial fermentation, and streamlined manufacturing processes.

Dyadic recently highlighted growing commercial activity with recombinant proteins and enzymes in non-pharmaceutical applications, including animal-free proteins for life sciences, cell culture media, nutrition, wellness, and industrial markets. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Additional studies have shown that C1-produced monoclonal antibodies can achieve binding and neutralization properties comparable to antibodies produced in traditional mammalian systems.